Among patients not on dialysis at baseline, vytorin did not reduce the risk of progressing to end-stage renal disease compared with placebo rr 0. 35676 continue reading
5 million to settle class-action lawsuits that accused them of withholding the unfavorable results of the enhance clinical trial of their cholesterol drugs vytorin and zetia. 12434 continue reading